Tazemetostat as a treatment for epithelioid sarcoma

References

• van Vliet M, Kliffen M, Krestin GP, et al. Soft tissue sarcomas at a glance: clinical, histological, and MR imaging features of malignant extremity soft tissue tumors. Eur Radiol. 2009 Jun 01;19(6):1499–1511.
   PubMed Web of Science ®Google Scholar
• Hatina J, Kripnerova M, Houfkova K, et al. Sarcoma stem cell heterogeneity. Adv Exp Med Biol. 2019;1123:95–118.
   PubMed Web of Science ®Google Scholar
• Enzinger FM. Epitheloid sarcoma. A sarcoma simulating a granuloma or a carcinoma. Cancer. 1970 Nov;26(5):1029–1041.
   PubMed Web of Science ®Google Scholar
• Armah HB, Parwani AV. Epithelioid sarcoma. Arch Pathol Lab Med. 2009 May;133(5):814–819.
   PubMed Web of Science ®Google Scholar
• de Visscher SA, van Ginkel RJ, Wobbes T, et al. Epithelioid sarcoma: still an only surgically curable disease. Cancer. 2006 Aug 1;107(3):606–612.
   PubMed Web of Science ®Google Scholar
• SEER*Stat Database, 1973-2014. [cited 2020 Apr 27]. Available from: https://seer.cancer.gov/archive/csr/1975_2014/results_merged/sect_34_soft_tissue_sarcomas.pdf
   Google Scholar
• Sobanko JF, Meijer L, Nigra TP. Epithelioid sarcoma: a review and update. J Clin Aesthet Dermatol. 2009 May;2(5):49–54.
   PubMedGoogle Scholar
• Thway K, Jones RL, Noujaim J, et al. Epithelioid sarcoma: diagnostic features and genetics. Adv Anat Pathol. 2016 Jan;23(1):41–49.
   PubMed Web of Science ®Google Scholar
• Chase DR, Enzinger FM. Epithelioid sarcoma. Diagnosis, prognostic indicators, and treatment. Am J Surg Pathol. 1985 Apr;9(4):241–263.
   PubMed Web of Science ®Google Scholar
• Guzzetta AA, Montgomery EA, Lyu H, et al. Epithelioid sarcoma: one institution’s experience with a rare sarcoma. J Surg Res. 2012 Sep;177(1):116–122.
   PubMed Web of Science ®Google Scholar
• Jawad MU, Extein J, Min ES, et al. Prognostic factors for survival in patients with epithelioid sarcoma: 441 cases from the SEER database. Clin Orthop Relat Res. 2009 Nov;467(11):2939–2948.
   PubMed Web of Science ®Google Scholar
• Jones RL, Constantinidou A, Olmos D, et al. Role of palliative chemotherapy in advanced epithelioid sarcoma. Am J Clin Oncol. 2012 Aug;35(4):351–357.
   PubMed Web of Science ®Google Scholar
• Pink D, Richter S, Gerdes S, et al. Gemcitabine and docetaxel for epithelioid sarcoma: results from a retrospective, multi-institutional analysis. Oncology. 2014;87(2):95–103.
   PubMed Web of Science ®Google Scholar
• Frezza AM, Jones RL, Lo Vullo S, et al. Anthracycline, gemcitabine, and pazopanib in epithelioid sarcoma: a multi-institutional case series. JAMA Oncol. 2018 Sep 1;4(9):e180219.
   PubMed Web of Science ®Google Scholar
• FDA approves tazemetostat for advanced epithelioid sarcoma; 2020 [cited 2020 May 14]. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tazemetostat-advanced-epithelioid-sarcoma
   Google Scholar
• Stacciotti S, Schoffski P, Jones RL, et al. Safety and efficacy of Tazemetostat, a first-in-class EZH2 inhibitor, in patients with epitheloid sarcoma (ES) (NCT02601950). Presented at the American Society of Clinical Oncology Conference; 2019; Chicago, IL.
   Google Scholar
• Schuetze SM, Bolejack V, Choy E, et al. Phase 2 study of dasatinib in patients with alveolar soft part sarcoma, chondrosarcoma, chordoma, epithelioid sarcoma, or solitary fibrous tumor. Cancer. 2017 Jan 1;123(1):90–97.
   PubMed Web of Science ®Google Scholar
• Ophanet- Epithelioid Sarcoma. The portal for rare diseases and orphan drugs; 2020 [cited 2020 May 14]. Available from: https://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=EN&Expert=293202
   Google Scholar
• Touati N, Schoffski P, Litiere S, et al. European organisation for research and treatment of cancer soft tissue and bone sarcoma group experience with advanced/metastatic epithelioid sarcoma patients treated in prospective trials: clinical profile and response to systemic therapy. Clin Oncol (R Coll Radiol). 2018 Jul;30(7):448–454.
   PubMed Web of Science ®Google Scholar
• Italiano A, Soria JC, Toulmonde M, et al. Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study. Lancet Oncol. 2018 May;19(5):649–659.
   PubMed Web of Science ®Google Scholar
• National Center for Biotechnology Information. PubChem database. Tazemetostat, CID=66558664 [cited 2020 May 18]]. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/Tazemetostat
   Google Scholar
• Huet S, Xerri L, Tesson B, et al. EZH2 alterations in follicular lymphoma: biological and clinical correlations. Blood Cancer J. 2017 Apr 21;7(4):e555.
   PubMedGoogle Scholar
• Morin RD, Johnson NA, Severson TM, et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet. 2010 Feb;42(2):181–185.
   PubMed Web of Science ®Google Scholar
• Versteege I, Sevenet N, Lange J, et al. Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. Nature. 1998 Jul 9;394(6689):203–206.
   PubMed Web of Science ®Google Scholar
• Lee RS, Stewart C, Carter SL, et al. A remarkably simple genome underlies highly malignant pediatric rhabdoid cancers. J Clin Invest. 2012 Aug;122(8):2983–2988.
   PubMed Web of Science ®Google Scholar
• Hollmann TJ, Hornick JL. INI1-deficient tumors: diagnostic features and molecular genetics. Am J Surg Pathol. 2011 Oct;35(10):e47–63.
   PubMed Web of Science ®Google Scholar
• Hornick JL, Dal Cin P, Fletcher CD. Loss of INI1 expression is characteristic of both conventional and proximal-type epithelioid sarcoma. Am J Surg Pathol. 2009 Apr;33(4):542–550.
   PubMed Web of Science ®Google Scholar
• Kohashi K, Oda Y. Oncogenic roles of SMARCB1/INI1 and its deficient tumors. Cancer Sci. 2017 Apr;108(4):547–552.
   PubMed Web of Science ®Google Scholar
• Wilson BG, Wang X, Shen X, et al. Epigenetic antagonism between polycomb and SWI/SNF complexes during oncogenic transformation. Cancer Cell. 2010 Oct 19;18(4):316–328.
   PubMed Web of Science ®Google Scholar
• Kadoch C, Hargreaves DC, Hodges C, et al. Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy. Nat Genet. 2013 Jun;45(6):592–601.
   PubMed Web of Science ®Google Scholar
• Hohmann AF, Vakoc CR. A rationale to target the SWI/SNF complex for cancer therapy. Trends Genet. 2014 Aug;30(8):356–363.
   PubMed Web of Science ®Google Scholar
• Therasse P, Eisenhauer EA, Verweij J. RECIST revisited: a review of validation studies on tumour assessment. Eur J Cancer. 2006 May;42(8):1031–1039.
   PubMed Web of Science ®Google Scholar
• Choi H, Charnsangavej C, Faria SC, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol. 2007 May 1;25(13):1753–1759.
   PubMed Web of Science ®Google Scholar
• Ratain MJ, Eckhardt SG. Phase II studies of modern drugs directed against new targets: if you are fazed, too, then resist RECIST. J Clin Oncol. 2004 Nov 15;22(22):4442–4445.
   PubMed Web of Science ®Google Scholar
• Oncologic Drugs Advisory Committee Meeting: NDA 211723. Tazemetostat: hearing before the FDA briefing document; 2019 Dec 18.
   Google Scholar
• Italiano A. Targeting epigenetics in sarcomas through EZH2 inhibition. J Hematol Oncol. 2020 Apr 7;13(1):33.
   PubMed Web of Science ®Google Scholar
• Zingg D, Arenas-Ramirez N, Sahin D, et al. The histone methyltransferase Ezh2 controls mechanisms of adaptive resistance to tumor immunotherapy. Cell Rep. 2017 Jul 25;20(4):854–867.
   PubMed Web of Science ®Google Scholar
• Zhou L, Mudianto T, Ma X, et al. Targeting EZH2 enhances antigen presentation, antitumor immunity, and circumvents anti-PD-1 resistance in head and neck cancer. Clin Cancer Res. 2020 Jan 1;26(1):290–300.
   PubMed Web of Science ®Google Scholar
• Schoffski P, Agulnik M, Stacchiotti S, et al. Phase 2 multicenter study of the EZH2 inhibitor tazemetostat in adults with synovial sarcoma (NCT02601950). J clin oncol. 2017;35(15_suppl):11057.
   Google Scholar